Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma
- 27 December 2010
- journal article
- dermatopathology
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 164 (5) , 1052-1060
Abstract
Background ‘FOXP3+ regulatory T cells’ (Tregs) are reported to be increased in tumour‐bearing hosts including patients with melanoma, leading to tumour immune suppression. However, this idea is challenged by recent evidence that the ‘FOXP3+ Treg’ fraction in fact contains activated ‘nonregulatory’ T cells. Also, FOXP3+ T cells are reported to have functionally and kinetically distinct subsets. Objectives To investigate whether either or both of regulatory and ‘nonregulatory’ FOXP3+ T cells are perturbed in patients with melanoma. Methods FOXP3+ T cells were classified into three subsets, namely CD45RO+FOXP3low nonregulatory T cells, CD45RO+FOXP3high effector Tregs, and CD45RO−FOXP3low naïve Tregs, according to their expression levels of FOXP3 and CD45RO. The percentage and cytokine production of these FOXP3+ T‐cell subsets were assessed by flow cytometry. Results Both regulatory and nonregulatory T cells were increased in patients with melanoma. Moreover, we found three unexpected perturbations in FOXP3+ T‐cell subsets: (i) patients with melanoma showed higher frequencies of FOXP3low nonregulatory T cells, which decreased and normalized after tumour removal; (ii) FOXP3low naïve Tregs containing higher frequencies of interferon‐γ+ cells increased with tumour progression; and (iii) CD45RO+FOXP3high effector Tregs were pronouncedly infiltrated around tumour tissues. Conclusions These findings demonstrate that patients with melanoma have distinct and differential perturbation of both regulatory and nonregulatory FOXP3+ T cells. The degree of perturbation is associated with tumour burden and progression, suggesting that the perturbation reflects fundamental pathophysiological processes in patients with melanoma. The presented analysis provides a practical approach to investigate the immunological environment of cancer patients.Keywords
This publication has 29 references indexed in Scilit:
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription FactorImmunity, 2009
- The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammationNature Immunology, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesionsBlood, 2008
- Regulatory T cells and tumour immunity – observations in mice and menImmunology, 2007
- Induction of FOXP3 expression in naive human CD4+FOXP3− T cells by T-cell receptor stimulation is transforming growth factor-β–dependent but does not confer a regulatory phenotypeBlood, 2007
- T cell immune reconstitution following lymphodepletionSeminars in Immunology, 2007
- Transient expression of FOXP3 in human activated nonregulatory CD4+ T cellsEuropean Journal of Immunology, 2006
- Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivoJournal of Clinical Investigation, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006